Cargando…

Clever-1 positive macrophages in breast cancer

PURPOSE: Common Lymphatic Endothelial and Vascular Endothelial Receptor 1 (Clever-1) is expressed by a subset of immunosuppressive macrophages and targeting the receptor with therapeutic antibodies has been shown to activate T-cell-mediated anti-cancer immunity. The aim of this research was to study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mutka, Minna, Virtakoivu, Reetta, Joensuu, Kristiina, Hollmén, Maija, Heikkilä, Päivi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464734/ https://www.ncbi.nlm.nih.gov/pubmed/35917053 http://dx.doi.org/10.1007/s10549-022-06683-4

Ejemplares similares

Enhanced Antibody Production in Clever-1/Stabilin-1–Deficient Mice
por: Dunkel, Johannes, et al.
Publicado: (2018)

Lymphatic Endothelial Cell Activation and Dendritic Cell Transmigration Is Modified by Genetic Deletion of Clever-1
por: Tadayon, Sina, et al.
Publicado: (2021)

Core needle biopsies alter the amounts of CCR5, Siglec-15, and PD-L1 positivities in breast carcinoma
por: Mutka, Minna, et al.
Publicado: (2023)

Quantities of CD3+, CD8+ and CD56+ lymphocytes decline in breast cancer recurrences while CD4+ remain similar
por: Mutka, Minna, et al.
Publicado: (2023)

Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry
por: Wirtz, Ralph M., et al.
Publicado: (2016)

The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + and CD8 +) and tumor-associated macrophages in early HER2 + breast cancer
por: Jääskeläinen, Minna M., et al.
Publicado: (2023)

New tools to prevent cancer growth and spread: a ‘Clever’ approach
por: Hollmén, Maija, et al.
Publicado: (2020)

Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis
por: Tiainen, Satu, et al.
Publicado: (2019)

Breast cancer outcome prediction with tumour tissue images and machine learning
por: Turkki, Riku, et al.
Publicado: (2019)

The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype
por: Tiainen, Satu, et al.
Publicado: (2020)

Assessing the role of tumour-associated macrophage subsets in breast cancer subtypes using digital image analysis
por: Zwager, Mieke C., et al.
Publicado: (2023)

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2021)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families
por: Muranen, Taru A., et al.
Publicado: (2016)

The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer
por: Eustace, A. J., et al.
Publicado: (2021)

Nonclinical Characterization of Bexmarilimab, a Clever-1–Targeting Antibody for Supporting Immune Defense Against Cancers
por: Hollmén, Maija, et al.
Publicado: (2022)

Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
por: Virtakoivu, Reetta, et al.
Publicado: (2021)

Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis
por: Lewis Phillips, Gail D., et al.
Publicado: (2017)

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics
por: Groenendijk, Floris H., et al.
Publicado: (2013)

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer
por: Han, Jinil, et al.
Publicado: (2017)

A distinct M2 macrophage infiltrate and transcriptomic profile decisively influence adipocyte differentiation in lipedema
por: Wolf, Stefan, et al.
Publicado: (2022)

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013)

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
por: Li, Kai, et al.
Publicado: (2020)

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer
por: El Ansari, Rokaya, et al.
Publicado: (2020)

MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis
por: Dutta, Pranabananda, et al.
Publicado: (2018)

Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention
por: Walter, Katherine R., et al.
Publicado: (2018)

Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China
por: Liu, Xiaoran, et al.
Publicado: (2021)

A prospective cohort study of clinical characteristics and outcomes in Chinese patients with estrogen receptor-negative/progesterone receptor-positive early breast cancer
por: Fan, Yu, et al.
Publicado: (2023)

Biological and clinical significance of PARP1 protein expression in breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

FOXA1 is a determinant of drug resistance in breast cancer cells
por: Kumar, Uttom, et al.
Publicado: (2021)

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2020)

Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol
por: van Loevezijn, Ariane A., et al.
Publicado: (2022)

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
por: Hida, Akira I., et al.
Publicado: (2016)

Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case–control study
por: Sui, Lin, et al.
Publicado: (2023)

The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
por: Narbe, Ulrik, et al.
Publicado: (2019)

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
por: Dubash, Taronish D., et al.
Publicado: (2023)

Heat shock factor 1 induces cancer stem cell phenotype in breast cancer cell lines
por: Wang, Bin, et al.
Publicado: (2015)

PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy
por: Fan, Yu, et al.
Publicado: (2022)

Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients
por: Erber, Ramona, et al.
Publicado: (2020)

Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8t0m5chbmuj2riq99pgrteh46u